Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis-Reference-Cited by-同舟云学术

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

Published:2003-01 Issue:1 Volume:31 Page:12-19
ISSN:0090-3493
Container-title:Critical Care Medicine
language:en
Short-container-title:Critical Care Medicine

Author:

Ely E. Wesley,Laterre Pierre-François,Angus Derek C.,Helterbrand Jeffrey D.,Levy Howard,Dhainaut Jean-François,Vincent Jean-Louis,Macias William L.,Bernard Gordon R.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Critical Care and Intensive Care Medicine

Reference32 articles.

1. APACHE II

2. Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis

3. Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial

4. Subgroup analysis and other (mis)uses of baseline data in clinical trials

Cited by 252 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anticoagulant therapies against sepsis‐induced disseminated intravascular coagulation;Acute Medicine & Surgery;2023-01

2. Machine Learning Approaches for Phenotyping in Cardiogenic Shock and Critical Illness;JACC: Advances;2022-10

3. Personalized Medicine for the Critically Ill Patient: A Narrative Review;Processes;2022-06-16

4. ICU Management: Disseminated Intravascular Coagulation (DIC);Textbook of Polytrauma Management;2022

5. Outcome of Early Hemostatic Intervention in Children With Sepsis and Nonovert Disseminated Intravascular Coagulation Admitted to PICU: A Randomized Controlled Trial;Pediatric Critical Care Medicine;2020-10-12